Movement Alert｜EVEREST MED Falls 5.32% in Regular Trading, UBS Downgrade Pressures Sentiment

Market Focus10-22

On October 22, EVEREST MED fell 5.32% in regular trading, trading at HK$34.24, with turnover of HK$101 million.

The clearest catalyst is an event-driven shift in sell-side sentiment: UBS downgraded the stock to Neutral and set a target price of RMB27, putting direct pressure on the shares after a prior run-up tied to enthusiasm around the company’s mRNA platform.

Earlier market optimism had centered on expectations for faster global clinical development of EVEREST MED’s in-house mRNA platform, including the hiring of two former Moderna core scientists and progress in EVM16 and EVM14 clinical programs. Against that backdrop, the latest downgrade appears to have prompted profit-taking following the earlier strength.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment